Therapeutic drug monitoring (TDM) is widely applied to a variety of medications, including antibiotics, immunosuppressants, and antidepressants, but the clinical utility of TDM for anticancer agents is currently limited by several factors. The primary reason is the poorly-deˆned concentration-eŠect relationships for most anticancer drugs. TDM has the potential to improve the clinical use of anticancer agents. This paper reviews the relations between the pharmacokinetics of a new anticancer agent, amrubicin, and the clinical response and toxic side eŠects in patients. The plasma concentration of amrubicin peaked immediately after a bolus intravenous injection of the drug and declined in a biexponential manner thereafter, whereas that of C-13 hydroxy metabolite amrubicinol also peaked just after amrubicin injection but decreased more gradually compared with that of amrubicin. The apparent total clearance of amrubicin showed a large interindividual variability, despite adjustment of dosage for body surface area. Leukocytopenia of grades 3 or 4 occurred in most patients, and thrombocytopenia and anemia of grades 3 or 4 were also common. Since the area-under the curves of amrubicin and amrubicinol seemed to be associated with the severity of hematological toxicities, it is thought that the plasma concentration of amrubicin and amrubicinol may provide useful information for establishing the optimal dosage of amrubicin in each patient.
Non-Small-Cell Lung Cancer, SCLC: Small-Cell Lung Cancer. ECOG performance status, these scales and criteria are used to assess how a patient's disease is progressing, assess how the disease aŠects the daily living abilities of the patient, and determine appropriate treatment and prognosis. 0: Fully active, able to carry on all pre-disease performance without restriction. 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, o‹ce work. 2: Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50％ of waking hours. No. of patients The AUC ratio refers to the ratio of the AUC 0 24 of amrubicinol to that of amrubicin. Treatment stopped after the second daily dose in one patient due to toxicity. The value represents mean value. 
